Display options
Share it on

Med Pharm Rep. 2021 Aug;94:S11-S14. doi: 10.15386/mpr-2219. Epub 2021 Aug 10.

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports

Raluca Tomoaia, Ruxandra Beyer, Simona Manole, Alina Chirilă, Alexandra Dădârlat-Pop, Ioan Alexandru Minciună, Dana Pop

Affiliations

  1. 5 Internal Medicine Department, Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  2. "N. Stancioiu" Heart Institute, Cluj-Napoca, Romania.
  3. Cardiology Department, Rehabilitation Hospital, Cluj-Napoca, Romania.

PMID: 34527900 PMCID: PMC8411828 DOI: 10.15386/mpr-2219

Abstract

Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated. We report the case of a patient with hereditary TTR amyloidosis and mixed phenotype (both cardiac and neurological involvement). We highlight the importance of multimodal imaging in the evaluation of these patients, as early diagnosis and treatment might lead to better outcome.

Keywords: TTR amyloidosis; multimodality imaging; transthyretin

References

  1. Ann Med. 2015;47(8):625-38 - PubMed
  2. Eur Heart J. 2015 Oct 7;36(38):2585-94 - PubMed
  3. JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277 - PubMed
  4. JAMA Cardiol. 2016 Nov 1;1(8):880-889 - PubMed
  5. Circ Heart Fail. 2018 Apr;11(4):e004769 - PubMed
  6. Circulation. 2019 Jul 2;140(1):16-26 - PubMed
  7. Circ Cardiovasc Imaging. 2013 Nov;6(6):1066-72 - PubMed
  8. Circulation. 2020 Jul 7;142(1):e7-e22 - PubMed
  9. N Engl J Med. 2018 Sep 13;379(11):1007-1016 - PubMed
  10. J Community Genet. 2018 Jan;9(1):93-99 - PubMed
  11. Curr Treat Options Oncol. 2020 Apr 23;21(5):36 - PubMed

Publication Types